2006 AVAC Report AIDS Vaccines: The Next Frontiers

In this year's AVAC Report, AVAC offers its first contribution to the scenario planning that we think is critical to the success of the field. The next several years will bring a variety of scenarios which we cannot encounter unprepared. Instead, the AIDS vaccine field, and the field of prevention research in general, must engage in rigorous debate, dialogue and scenario planning which anticipates the issues that the next few years will bring, and ensures that the wide range of stakeholders are informed and empowered to make decisions to compete against the virus. In this report, we present four thought-provoking chapters, each of which begins with a future scenario that considers how the world might look in five or six or ten years' time.

AIDS Vaccines: The Next Frontiers full PDF

Executive Summary
Table of Contents
Letter from the Board President and Executive Director


Chapter 1: AIDS Vaccine Science, Strategy and Action: The state of the field, the stakes for the future
This chapter provides an update on the state of AIDS vaccine science and science management, including an analysis of the Global HIV Vaccine Enterprise and its ongoing search for an executive director; and of the new Enterprise-related funding streams which emerged in 2005-2006.
Box 2: Update on the Global HIV Vaccine Enterprise
Figure 1: Understanding the Cosmology of the Global HIV Vaccine Enterprise
Table 2: Trials of Preventive HIV/AIDS Vaccines Worldwide
 
Chapter 2: Reports from the Frontlines: Learning from last year's clinical trials
This chapter analyzes successes and new challenges in the conduct of AIDS prevention clinical trials and concludes that a consensus on "good community practice" is needed. Look for an upcoming draft set of "GCP" guidelines that could help the scientific community and communities in the field ensure that every trial that is initiated meets agreed-upon criteria for substantive and sustainable engagement with the issues.
Box 5: What Would Make Multi-Functional Sites a Reality? Perspectives from South Africa
 
Chapter 3: The Emerging Adolescent Agenda: HPV vaccine, AIDS prevention research, and the new opportunities for reaching the young people of the world
This chapter explores why licensure of the vaccine against human papillomavirus (HPV) presents the AIDS vaccine field with new opportunities. AVAC calls on the field to advocate for financing commitments to ensure widespread access to the vaccine; document and learn from HPV experiences with trials and pilot programs among adolescents; and collaborate on advocacy and communication campaigns at every level.
Table 3: HPV Vaccine and HIV Vaccines: How Do They Compare?
 
Chapter 4: AIDS Prevention Evolves (Again): Why we are on the verge of an era of new complexity?
This chapter outlines why the next few years will bring developments that make AIDS vaccine research more complicated, though no less necessary.
Table 4:Trials of New Prevention Options Worldwide
Figure 6: Research That Could Redefine Prevention: Timeline of Anticipated Results